Join The Conversation Card Front 01 Copy

The Medtechy Daily: November 2

Posted on November 02, 2018 by Medtech[y] Staff

The Medtechy Daily provides the latest news and insight for the medical technology industry, including medical device, biotech and digital health.

Tweet of the Day


The CEO of a big New York hospital explains why he wants everyone in the US to have health coverage — but doesn't support 'Medicare for All'. Corwin is the CEO of NewYork-Presbyterian Hospital. Surgeries, intensive care, and other costly procedures are constantly taking place within its walls. Hospital care cost about $1.1 trillion in 2016 — that's 32% of health spending in the US. (Business Insider)

Stimwave Receives FDA Clearance for WaveCrest Mobile iOS Platform Patient Controllers. Stimwave Technologies announced that they received FDA clearance for the WaveCrest Mobile iOS Platform patient controllers for opioid free pain management, which gives patients iPhone and Apple Watch mobile control over WaveMaster multi-waveform automated programming for the Wireless Freedom Spinal Cord Stimulator (SCS) System for relief of chronic pain. (Medtechy)

APPLE'S HEART STUDY IS THE BIGGEST EVER, BUT WITH A CATCH. Last November, Apple Watch owners began receiving recruitment emails from Apple. The company was looking for owners of its smartwatch to participate in the Apple Heart Study—a Stanford-led investigation into the wearable's ability to sense irregular heart rhythms. (Wired)

Two New Studies Warn Against Minimally Invasive Surgery for Cervical Cancer. The New England Journal of Medicine published two studies Wednesday that could deal a blow to minimally invasive surgery for Cervical Cancer. (Medtechy)

Health Care in the 2018 Election. The outcome of the 2018 midterm congressional election is important to the future of health care in the United States. Since 1994, the division between those who identify as Republicans and those who identify as Democrats has grown on a range of domestic policy issues, including many major health care topics. (NEJM)

Botox Drives Allergan Earnings. Allergan raised full-year 2018 revenue guidance and announced $3.91 billion in sales for the third quarter, a 3% decrease from the prior year quarter. While overall revenue decreased, there were continued bright spots by Allergan's key promoted brands which represented nearly 90 percent of total revenues, growing 5.9 percent versus prior year. (Medtechy)